References of "Noël, Agnes"
     in
Bookmark and Share    
Peer Reviewed
See detailMicroRNA-146a is a causative factor and a specific biomarker for peripartum cardiomyopathy
Halkein, Julie ULg; Tabruyn, Sébastien ULg; Haghikia, Arash et al

Poster (2012, April)

Detailed reference viewed: 39 (1 ULg)
Peer Reviewed
See detailMiR-146a an angiostatic miRNA elevated in peripartum cardiomyopathy
Halkein, Julie ULg; Tabruyn, Sébastien ULg; Haghikia, Arash et al

Poster (2012, January)

Detailed reference viewed: 36 (0 ULg)
Peer Reviewed
See detailMiR-146a an angiostatic miRNA elevated in peripartum cardiomyopathy
Halkein, Julie ULg; Castermans, Karolien; Malvaux, Ludovic et al

Poster (2011, March)

Detailed reference viewed: 8 (2 ULg)
Peer Reviewed
See detailMir-146a : A new angiostatic miRNA with tumor-suppressive properties
Halkein, Julie ULg; Castermans, Karolien; Malvaux, Ludovic et al

Poster (2011, March)

Detailed reference viewed: 5 (1 ULg)
Peer Reviewed
See detailmicroRNA-21 Exhibits Anti-Angiogenic Function by Targeting RhoB Expression in Endothelial Cells
Sabatel, Céline; Malvaux, Ludovic; Bovy, Nicolas ULg et al

Poster (2011, February)

Detailed reference viewed: 6 (1 ULg)
Peer Reviewed
See detailMiR-146a an angiostatic miRNA elevated in peripartum cardiomyopathy
Halkein, Julie ULg; Castermans, Karolien; Malvaux, Ludovic et al

Poster (2011, February)

Detailed reference viewed: 5 (0 ULg)
Peer Reviewed
See detailMiR-146a: an angiostatic miRNA with tumor-suppressive properties
Halkein, Julie ULg; Bovy, Nicolas ULg; Castermans, Karolien et al

Poster (2011, February)

Detailed reference viewed: 10 (2 ULg)
Full Text
See detailNovel HDAC/DNMT Twin inhibitors interfere with angiogenesis
Shiva Shankar, Thammadihalli Veerasangaiah ULg; Sulka, Béatrice ULg; Blacher, Silvia ULg et al

Poster (2011, January 31)

DNA methylation and histone deacetylation are two key epigenetic modifications that play central role in regulation of gene expression. Several studies have shown that histone deacetylases (HDAC) and DNA ... [more ▼]

DNA methylation and histone deacetylation are two key epigenetic modifications that play central role in regulation of gene expression. Several studies have shown that histone deacetylases (HDAC) and DNA methyltransferases (DNMT) inhibitors are potent anti-angiogenic compounds. Though combination of HDAC and DNMT inhibitors are now being examined in clinical trials of hematological malignancies, little work has been done to understand the effect of this combination on physiological and tumoral angiogenesis. We have designed and tested a family of twin drugs with intrinsic HDAC and DNMT inhibitory activities in relevant models of angiogenesis in vitro (Human Umbilical Vein Endothelial Cells – HUVEC and aortic ring) and in vivo (chick chorioallantoic membrane and Zebrafish). We have identified a lead compound having quantifiable anti-angiogenic effect without cytotoxicity affecting global histone acetylation and DNA methylation levels. In order to elucidate its anti-angiogenic mechanism, we characterized gene expression pattern simultaneously with the methylation profile of HUVEC cells treated with the lead compound and reference epigenetic modulators. This approach based on parallel microarray analyses permitted us to underscore a list of genes exclusively affected by the lead compound but not by other HDAC or DNMT inhibitors. These genes were then analyzed using the Ingenuity Pathway software revealing potential involvement of a subset of genes in angiogenesis. Our present aim is to validate the expression levels of a series of genes with respect to epigenetic mechanisms (histone modifications and DNA methylation). Finally, the biological relevance of the target genes will be explored by RNA silencing. Hence, we are using these novel epigenetic modulators as a tool to understand the regulatory mechanism of angiogenesis and to develop effective approaches to treat cancer. [less ▲]

Detailed reference viewed: 65 (15 ULg)
Peer Reviewed
See detailMiR-146a an angiostatic miRNA elevated in peripartum cardiomyopathy
Halkein, Julie ULg; Castermans, Karolien; Malvaux, Ludovic et al

Poster (2011, January)

Detailed reference viewed: 8 (1 ULg)
Full Text
Peer Reviewed
See detailNovel HDAC/DNMT Twin Inhibitors Interfere with Angiogenesis
Shiva Shankar, Thammadihalli Veerasangaiah ULg; Sulka, Béatrice ULg; Blacher, Silvia ULg et al

Poster (2011)

DNA methylation and histone deacetylation are two key epigenetic modifications that play central role in regulation of gene expression. Several studies have shown that histone deacetylases (HDAC) and DNA ... [more ▼]

DNA methylation and histone deacetylation are two key epigenetic modifications that play central role in regulation of gene expression. Several studies have shown that histone deacetylases (HDAC) and DNA methyltransferases (DNMT) inhibitors are potent anti-angiogenic compounds. Though combination of HDAC and DNMT inhibitors are now being examined in clinical trials of hematological malignancies, little work has been done to understand the effect of this combination on physiological and tumoral angiogenesis. We have designed and tested a family of twin drugs with intrinsic HDAC and DNMT inhibitory activities in relevant models of angiogenesis in vitro (Human Umbilical Vein Endothelial Cells – HUVEC and aortic ring) and in vivo (chick chorioallantoic membrane and Zebrafish). We have identified a lead compound having quantifiable anti-angiogenic effect without cytotoxicity affecting global histone acetylation and DNA methylation levels. In order to elucidate its anti-angiogenic mechanism, we characterized gene expression pattern simultaneously with the methylation profile of HUVEC cells treated with the lead compound and reference epigenetic modulators. This approach based on parallel microarray analyses permitted us to underscore a list of genes exclusively affected by the lead compound but not by other HDAC or DNMT inhibitors. These genes were then analyzed using the Ingenuity Pathway software revealing potential involvement of a subset of genes in angiogenesis. Our present aim is to validate the expression levels of a series of genes with respect to epigenetic mechanisms (histone modifications and DNA methylation). Finally, the biological relevance of the target genes will be explored by RNA silencing. Hence, we are using these novel epigenetic modulators as a tool to understand the regulatory mechanism of angiogenesis and to develop effective approaches to treat cancer. [less ▲]

Detailed reference viewed: 187 (53 ULg)
Peer Reviewed
See detailMir-146a : A new angiostatic miRNA with tumor-suppressive properties
Halkein, Julie ULg; Castermans, Karolien; Malvaux, Ludovic et al

Poster (2010, October)

Detailed reference viewed: 7 (0 ULg)
Full Text
Peer Reviewed
See detailNovel HDAC/DNMT twin inhibitors interfere with angiogenesis
Shiva Shankar, Thammadihalli Veerasangaiah ULg; Sulka, Béatrice; Blacher, Silvia ULg et al

Poster (2010)

DNA methylation and histone deacetylation are two key epigenetic modifications that play central role in regulation of gene expression. Several studies have shown that histone deacetylases (HDAC) and DNA ... [more ▼]

DNA methylation and histone deacetylation are two key epigenetic modifications that play central role in regulation of gene expression. Several studies have shown that histone deacetylases (HDAC) and DNA methyltransferases (DNMT) inhibitors are potent antiangiogenic compounds. Though combination of HDAC and DNMT inhibitors are now being examined in clinical trials of hematological malignancies, very little work has been done to understand the effect of this combination on normal and tumoral angiogenesis. We have designed and tested a family of twin drugs with intrinsic HDAC and DNMT inhibitory activities in relevant models of angiogenesis in vitro (endothelial cells, pericytes and the 3D aortic ring assay) and in vivo (the chick chorioallantoic membrane assay). We have identified a lead compound having quantifiable antiangiogenic effect without cytotoxicity associated with increased global acetylation and decreased DNA methylation levels. This compound is presently used to develop effective approaches to treat cancer by modulating the process of angiogenesis. [less ▲]

Detailed reference viewed: 182 (67 ULg)